3[2]Klocke RK. Effects of twenty - four hour milrinone infusion in patients with severe heart failure and cardiagenic shock as a function of the hemodynamic initial condition[J]. Am Heart J, 1991,121:1965
4[3]Erhardt PW. Cardiaotonic agents: A topograrphical model of the cardiac camp phosphodiesterase receptor[J ].Mol Pharmacol, 1988,33:1
5[4]Honerjager P. Pharmacology of positive inotropic phosphodiesterase ingibitors[ J ]. Eur Heart J, 1989,10: 25
6[6]Benotti JB. Pharmacokinetics and harmacodynamics of milrinone in chronic congestive heart failure[J ]. Am J Cardiol, 1985,56: 585
7[1]Panina G, Khot UN, Nunziata E, et al. Assessment of autonomic tone over a 24-hour period in patients with congestive heart failure: relation between mean heart rate and measures of heart rate variability. Am Heart J,1995,129:748-753.
8[4]Fei L, Keeling PJ, Giu JS, et al. Heart rate variability and relation to ventricular arrhythmias in congestive heart failure. Br Heart J, 1994,71:322-328.
9[7]赵水平.心脏内科研修精要.第1版.长沙:湖南科学技术出版社,2000.60.
10[8]Harding VB, Jones LR, Lefkowitz R J, et al. Cardiac beta ARK1 inhibition prolongs survival and augments beta bloker therapy in a mouse model of severe heart failure.Proc Natl Acad Sci U S A, 2001,98:5809-5814.
